Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a ...
Local Spotlight: Managing high bad cholesterol. High bad cholesterol is a risk factor for a common type of heart disease, yet ...
Radiant Pharmaceuticals Limited (RPL), one of the top healthcare solution providers in Bangladesh, is set to buy a majority ...
Novartis Bangladesh Limited (“NBL”) announced on Thursday that the agreement by Novartis AG to transfer its shares in NBL to ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
In a case-based competition, participants will be able to solve real-life problems in collaboration with experts from ...
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) on December 3 and set a price target of ...
Shares of Divi's Laboratories Ltd. are down by up to 6% on Thursday, December 5, following Novartis losing its appeal in a US ...
Novartis failed to block MSN generic Entresto launch after U.S. appeals court upheld a ruling against them. Explore the ...
The Managing Director of Novartis in Tyrol explains the reason for the "separation" from Sandoz, reveals the turnover for ...
The company's product is therapeutically equivalent to Novartis Pharmaceuticals Corporation's Votrient tablets (200 mg).
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities, has received USFDA approval to market Pazopanib Tablets (200 mg) in ...